Innovations Stem Cell Center (ISCC) champions a responsible approach to stem cell therapy. It follows one consistent, evidence-based protocol that uses stem cells derived from a patient’s fat to offer renewed hope for conditions considered untreatable by conventional methods. By applying the same protocol for every patient, ISCC makes results measurable and evidence reliable. Many clinics often change their methods, adding outside cells or biologics that raise costs and make unclear what truly works. ISCC removes that uncertainty, giving patients confidence in their care and delivering results that withstand scientific scrutiny. “We don’t tell patients anything we cannot back up with research or evidence. For example, if we say 83 percent of patients with knee problems respond to treatment, we can point to the supporting data,” says Dr. Bill Johnson, CEO. With more than four decades of experience in internal medicine, Dr. Johnson leads a team that has been with him since ISCC’s founding, uniting experience with precise execution. For much of his career, he was limited to managing chronic disease and helping patients cope rather than recover. Stem cell therapy has changed that, giving him the chance to catalyze genuine healing. That shift defines the way ISCC practices today. Patients also value the combination of clinical expertise and honest communication. They are given a realistic view of what stem cells can achieve and where uncertainties remain. This approach has already led to progress in diverse areas, from relieving joint pain and easing autoimmune flare-ups to improving neurologic symptoms, healing chronic wounds, and even changing the trajectory of early kidney and lung disease. A Simple Method for Multiplying Healing Cells A small amount of fat is removed under local anesthesia. The collagen that binds the fat cells is dissolved using collagenase, releasing the stem cells from the fat matrix. The sample is then centrifuged at a low speed to preserve the maximum number of viable stem cells. After thoroughly rinsing away enzymes, the result is a concentrated preparation containing tens of millions of the patient’s own stem cells. These cells are returned to the body via a sterile, closed system to prevent contamination and ensure protection.
Clinical Trial
As a company committed to advancing healthcare to serve the community better, Miami Clinical Research (MCR) has been at the top of its game in enhancing the quality of health and wellness through medical research. What has helped MCR is its solutions-focused approach and dedication to addressing the most pressing challenges in clinical trial management today. Clinical trials today are fraught with challenges. Patient recruitment and retention, regulatory complexities and the integration of technology into trial workflows are some of clients' most frequently cited pain points. Additionally, the pressure to reduce timelines while maintaining quality is a constant concern in an increasingly competitive field. For companies looking to expedite the development of life-saving therapies, these obstacles can seem insurmountable. MCR, however, has taken a proactive stance in addressing these issues through a multi-pronged strategy designed to offer not just solutions but sustainable success. Dr. Hoover, owner of BioResearch Partner SMO says, "We operate with a clear awareness of the pain points that clients face, ensuring that every decision and process is aligned to tackle these obstacles head-on. Through a unique combination of community engagement, cutting-edge technology and a commitment to patient care, we have carved out a reputation as a trusted ally in bringing new therapies to market. “.
Clinical Trial
Flex Databases has become the top choice for contract research organizations (CRO), pharmaceutical companies and academic institutions looking for innovative solutions to manage their clinical trials. The company’s intuitive and configurable platform supports all aspects of clinical trials while imparting flexibility and efficiency, with compliance as a key component. A major advantage of its platform is its flexibility. The no-code engine behind Flex Databases software allows users to easily customize it for their applications, eliminating costly and lengthy development cycles. This ensures that CROs can quickly respond to changing project needs, making the entire clinical trial process agile and efficient. “Our platform empowers CROs and sponsors to achieve and clearly demonstrate compliance. With a no-code approach, they benefit from a system that seamlessly adapts to their processes—offering a tailored, out-of-the-box solution without the need for additional development,” says Evgenia Michalčuk-Vráblík, Global Director of Growth. Embracing Efficiency Every Step of the Way The platform has five modules that serve distinct purposes, namely—electronic trial master file (eTMF), quality and learning management system, clinical operations activities management, budgets and payments management and pharmacovigilance. Each module is designed to operate seamlessly with the others, creating an integrated environment that streamlines operations..
Cell and Gene Therapy
Cellular Therapy: Recommendations for Developing a Cell Therapy Program
Robert Richards, Corporate Director of The Center for Cell Therapy and Transplant, Penn Medicine, University of Pennsylvania Health System
Cell and Gene Therapy
Construction and Maintenance Risks: It's Never Just Removing a Ceiling Tile
Nancy Warren, MHA, MLT (ASCP), CIC, Infection Control Manager, Fox Chase Cancer Center
Clinical Laboratory
Potency Assay Development to Bridge Clinical Data and Remove Variability
Cheryl Grove Cox, Cell Therapy Operations Director, Moffitt Cancer Center
Cell and Gene Therapy
Blood Flow Restriction Therapy (BFR): Entering Uncharted Territory
Corbin Hedt, PT, DPT, SCS, CSCS, Senior Physical Therapist, Upper Extremity Athlete Fellowship Director, Houston Methodist
Cell and Gene Therapy
Trends Impacting the MedTech Space
Gilbert Tang, Academic Director, Structural Heart Program, Mount Sinai Health System
Cell and Gene Therapy
The Rosy App's Success in Cervical Cancer Education
Lyndsey Harper, Attending Physician- Obstetrics and Gynecology, Baylor Scott & White Health
Cell and Gene Therapy
Improving Cardiovascular Care through System-Wide Leadership and Digital Innovation
James Cireddu, MD, FACC, System Director of Stress Testing, Harrington Heart & Vascular Institute, University Hospitals
IN MY OPINION
Cell and Gene Therapy
Putting Patients at the Heart of Safety and Accreditation
Sharon Gilliam, MSN, RN, Director of Patient Safety & Quality, Williamson Medical Center
LAST WORD
Cell and Gene Therapy
Breaking New Ground in Cancer Care
Dr. Ian Jasenof, Chief Medical Officer, Mile Square Health Center-UI Health; Cancer Center-Director of Strategic FQHC Partnerships, UI Health
IN FOCUS
The Digital Infrastructure Behind Translational Science in Cell and Gene Therapy
Stem cell therapy offers hope for curing previously untreatable diseases, with CTMS playing a crucial role in ensuring compliance, managing logistics, and accelerating clinical trial processes.
From Concept to Clinic: The New Era of Stem Cell Therapeutics
Stem cell therapy has transitioned from research to a burgeoning commercial industry, driven by scientific advancements, regulatory support, and significant investment, enabling scalable, personalized treatments.
EDITORIAL
The Promise of Stem Cell Therapy and Clinical Innovation
Among the most responsible leaders of this movement is Innovations Stem Cell Center (ISCC), a trailblazer in regenerative medicine. ISCC follows one consistent, evidence-based protocol using stem cells derived from a patient’s own fat, offering renewed hope for conditions once deemed untreatable by conventional methods. By applying the same protocol for every patient, ISCC ensures results are both measurable and scientifically reliable, setting a new gold standard for accountability in stem cell therapy. This disciplined approach bridges innovation with integrity, proving that progress and patient safety can advance hand in hand.
Supporting this clinical revolution are organizations providing comprehensive clinical trial services and next-generation CTMS platforms. These systems streamline every stage of research, from recruitment to data management that makes trials more efficient, compliant, and adaptive. They form the backbone of evidence collection, accelerating the translation of scientific discovery into real-world care.
We feature insights from two healthcare leaders shaping the transformative era. Robert Richards, Corporate Director of The Center for Cell Therapy and Transplant at the Penn Medicine, University of Pennsylvania Health System, emphasizes the critical importance of standardized cell therapy protocols to ensure patient safety and data integrity across clinical applications. Meanwhile, Sharon Gilliam, Director of Patient Safety & Quality at Williamson Medical Center, underscores that innovation must always align with rigorous quality assurance and ethical stewardship, ensuring that every breakthrough serves patients responsibly.
This edition explores how regenerative medicine, powered by robust clinical infrastructure and guided by responsible leadership, is reshaping the very definition of healing. It’s a movement from experimentation to evidence, from possibility to proof and a future built not just to treat, but to transform lives.
